Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients

Hepatology

Volumn 56, Issue 5, 2012, Pages 1751-1759

  Bedossa, Pierre ^a,b   Poitou, Christine ^c,d,f   Veyrie, Nicolas ^e   Bouillot, Jean Luc ^e   Basdevant, Arnaud ^c,d,f   Paradis, Valerie ^a,b   Tordjman, Joan ^c,d,f   Clement, Karine ^c,d,f  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ALGORITHMS; ANALYSIS OF VARIANCE; ASPARTATE AMINOTRANSFERASES; BIOPSY; FATTY LIVER; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OBESITY, MORBID; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84868235041     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25889     Document Type: Article

References (30)

1. Ratziu V, Voiculescu M, Poynard T. Touching some firm ground in the epidemiology of NASH. J Hepatol 2012; 56: 23-25.
2. Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56: 234-240.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004; 40: 1387-1395.
4. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
5. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
6. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. HEPATOLOGY 2002; 35: 367-372.
7. Flegal KM. Trends in body weight and overweight in the U.S. population. Nutr Rev 1996; 54: S97-100.
8. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600-606.
9. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. HEPATOLOGY 2011; 54: 344-353.
10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
11. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
12. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
13. Brunt EM, Kleiner DE, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Misuse of scoring systems. HEPATOLOGY 2011; 54: 369-370; author reply 370-361.
14. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. HEPATOLOGY 2011; 53: 1874-1882.
15. Scheuer PJ. Assessment of liver biopsies in chronic hepatitis: how is it best done? J Hepatol 2003; 38: 240-242.
16. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. HEPATOLOGY 2000; 31: 241-246.
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996; 24: 289-293.
18. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668.
19. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. HEPATOLOGY 2010; 51: 445-453.
20. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
21. Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. HEPATOLOGY 2008; 47: 1916-1923.
22. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. HEPATOLOGY 2011; 54: 1610-1619.
23. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. HEPATOLOGY 2011; 53: 810-820.
24. Poitou C, Coupaye M, Laaban JP, Coussieu C, Bedel JF, Bouillot JL, et al. Serum amyloid A and obstructive sleep apnea syndrome before and after surgically-induced weight loss in morbidly obese subjects. Obes Surg 2006; 16: 1475-1481.
25. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. HEPATOLOGY 2010; 52: 913-924.
26. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
27. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540.
28. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008; 48: 821-828.
29. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. HEPATOLOGY 2007; 45: 1366-1374.
30. Listenberger LL, Han X, Lewis SE, Cases S, Farese RVJr, Ory DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003; 100: 3077-3082.